|
|
 |
|
| Description |
The CD39 antibody specifically recognizes the membrane-bound human CD39 antigen, which is expressed on an effector/memory-like subset of FoxP3+ regulatory T cells1. CD39 is an ectonucleotidase and catalyzes the hydrolysis of extracellular nucleotides, for example, ATP. In concert with CD73, which is an ecto-5’-nucleotidase, this can lead to the production of adenosine. High extracellular ATP concentrations indicate tissue injury and cell death and induce various pro-inflammatory responses in immune cells. Through its enzymatic activity, CD39 can contribute to the suppressive function of regulatory T cells, for example, by eliminating extracellular ATP or by generating adenosine, which has suppressive effects on various immune cells. |
| Applications |
| The CD39 antibody can be used to identify and enumerate CD39+ regulatory T cells and other cells expressing CD39. |
| Cross-reactivity |
| Rhesus monkey (Macaca mulatta) |
| Clone | Isotype |
| MZ18-23C8 | mouse IgG1 |
| |
| Figure 1 |
| Human PBMCs were stained with CD4-FITC and CD39-PE (A). Furthermore, to evaluate CD39 expression on regulatory T cells, CD4+ T cells were enriched using the CD4+ T Cell Isolation Kit II and cells were stained with CD39-APC and Anti-FoxP3-PE (B). |
| A |
 |
| B |
 |
|
|
|
 |
| My favorites |
| Your current favorite list is empty. |
|
| Products |
| CD39-FITC, human |
- for 100 tests (1) Download datasheet 130-093-502
|
| CD39-PE, human |
- for 100 tests (1) Download datasheet 130-093-503
|
| CD39-APC, human |
- for 100 tests (1) Download datasheet 130-093-504
|
| CD39-Biotin, human |
- for 100 tests (2) Download datasheet 130-093-505
|
| CD39 pure, human |
- 100 μg in 1 mL Download datasheet 130-093-506
|
| (1) One test corresponds to fluorescent labeling of up to 107 cells in a total volume of 100 μL. |
| (2) One test corresponds to labeling of up to 107 cells in a total volume of 100 μL. |
|
| References |
| 1. Borsellino et al. (2007) Blood 110: 1225–1232. |
|
|
|
© 1999 - 2010 Miltenyi Biotec ¦ Terms & conditions ¦ Legal notes
|